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ABSTRACT
Immune selection drives tumor cells to acquire refractory phenotypes. We previously demonstrated that 
cytotoxic T lymphocyte (CTL)-mediated immune pressure enriches NANOG+ tumor cells with stem-like 
and immune-refractory properties that make them resistant to CTLs. Here, we report that the emergence 
of refractory phenotypes is highly associated with an aberrant macroautophagic/autophagic state of the 
NANOG+ tumor cells and that the autophagic phenotype arises through transcriptional induction of 
MAP1LC3B/LC3B by NANOG. Furthermore, we found that upregulation of LC3B expression contributes to 
an increase in EGF secretion. The subsequent hyperactivation of EGFR-AKT signaling rendered NANOG+ 
tumor cells resistant to CTL killing. The NANOG-LC3B-p-EGFR axis was preserved across various types of 
human cancer and correlated negatively with the overall survival of cervical cancer patients. Inhibition of 
LC3B in immune-refractory tumor models rendered tumors susceptible to adoptive T-cell transfer, as 
well as PDCD1/PD-1 blockade, and led to successful, long-term control of the disease. Thus, our findings 
demonstrate a novel link among immune-resistance, stem-like phenotypes, and LC3B-mediated autop-
hagic secretion in immune-refractory tumor cells, and implicate the LC3B-p-EGFR axis as a central 
molecular target for controlling NANOG+ immune-refractory cancer.
Abbreviations: ACTB: actin beta; ATG7: autophagy related 7; BafA1: bafilomycin A1; CASP3: caspase 3; 
CFSE: carboxyfluorescein succinimidyl ester; ChIP: chromatin immunoprecipitation; CI: confidence interval; 
CIN: cervical intraepithelial neoplasia; CSC: cancer stem cell; CTL: cytotoxic T lymphocyte; EGF: epidermal 
growth factor; EGFR: epidermal growth factor receptor; FIGO: International Federation of Gynecology and 
Obstetrics; GFP: green fluorescent protein; GZMB: granzyme B; HG-CIN: high-grade CIN; IHC: immunohis-
tochemistry; LG-CIN: low-grade CIN; LN: lymph node; MAP1LC3B/LC3B: microtubule associated protein 1 
light chain 3 beta; MCL1: myeloid cell leukemia sequence 1; MLANA/MART-1: melanoma antigen recog-
nized by T cells 1; MUT: mutant; NANOG: Nanog homeobox; PDCD1/PD-1: programmed cell death 1; 
PMEL/gp100: premelanosome protein; RTK: receptor tyrosine kinase; TMA: tissue microarray; WT: wild type
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Cancer immune therapy, in particular, T cell-based therapeu-
tic methods, such as adoptive T cell transfer and immune 
checkpoint blockades, has made tremendous progress in the 
field of anti-cancer therapy. Although cancer immunotherapy 
has emerged as a potentially powerful approach to cancer 
treatment, the presence of immunotherapeutic resistance lim-
its its clinical application [1]. In this regard, results from 
recent studies emphasized that cancer immunoediting drove 
the adaptation of tumor cells to host immune surveillance, 
thereby contributing to a generation of cancer cells with better 
survival advantages [2–5]. Therefore, it is necessary to 
improve our understanding of the molecular mechanisms by 
which immune editing promotes the immune-refractory phe-
notypes of tumor cells in order to develop more effective 
immune-based cancer therapies.
In an effort to elucidate the molecular mechanisms 
underlying cancer immunoediting, we previously found 
that cytotoxic T lymphocyte (CTL)-mediated immune selec-
tion caused the enrichment of a subset of cells with high 
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expression of NANOG (Nanog homeobox) [5]. These 
NANOG+ cells exhibited stem-like and anti-apoptotic prop-
erties and were resistant to CTL killing by hyperactivation of 
the AKT signaling pathway, indicating an important role of 
NANOG signaling in these refractory phenotypes of 
immune-resistant tumor cells [5–7]. Thus, these results pro-
pose a rationale whereby strategies impeding NANOG may 
overcome not only the problem of immune resistance but 
also that of the stem-like state of tumor cells. Given that 
clinically available NANOG pharmacologic inhibitors have 
not yet been developed, it is necessary to identify additional 
pathways that can be targeted to enhance the efficacy of 
immunotherapy.
Autophagy is a fundamental biological process that 
maintains intracellular homeostasis by degrading proteins 
and cytosolic contents and is induced by various forms of 
cellular stress including nutrient deprivation [8,9]. The 
process requires sequestration of cytoplasmic material by 
a transient compartment termed the phagophore, which 
matures into a double-membrane autophagosome [10]. 
The role of autophagy in cancer is quite complicated and 
still somewhat controversial; it appears to be tumor sup-
pressive during cancer development, but it is required for 
tumor maintenance and the progression to advanced dis-
ease [11,12]. The tumor-promoting functions of autophagy 
are largely ascribed to its importance as a survival pathway 
in response to diverse environmental stresses [13,14]. For 
example, enhanced autophagy has been observed in cancer 
stem cells (CSCs), a subset of stem-like tumor cells with an 
undifferentiated phenotype contributing to initial tumor 
formation and recurrence, and the maintenance of meta-
bolic homeostasis and cell viability, which promoted the 
resistance of CSCs to micro-environmental stresses, such 
as hypoxia, starvation or anti-cancer treatment [15,16]. 
Moreover, inhibition of autophagy can promote apoptosis 
and sensitize tumor cells to chemotherapy, radiotherapy, 
or immunotherapy [17–19]. Despite the crucial roles of 
autophagy in the maintenance of the stem-like state, as 
well as the survival of tumor cells against therapeutic 
multi-modalities, the potential link between immune resis-
tance and autophagy is poorly established.
Here, we demonstrate for the first time to our knowl-
edge that immune selection causes enrichment of a subset 
of tumor cells with aberrant autophagic phenotypes. The 
phenotype of these cells was critically dependent on 
MAP1LC3B/LC3B, which is a direct transcriptional target 
of NANOG. Unexpectedly, we observed that LC3B upregu-
lation led to an increase of autophagosome abundance 
within tumor cells, which contributed to EGF (epidermal 
growth factor) secretion and, consequentially, activation of 
the EGFR (epidermal growth factor receptor)-AKT signal-
ing pathway. Importantly, the inhibition of LC3B using 
siRNA could sensitize the refractory tumor to T-cell based 
immunotherapy, as well as the immune checkpoint block-
ade, by reversing the immune resistance of tumor cells to 
CTL killing and re-invigorating the cancer-immunity cycle. 
Thus, our findings indicate that LC3B inhibition is 
a promising strategy to control NANOG+ immune- 
refractory cancer, particularly in the context of immune- 
based therapy.
Results
Immune-resistant tumor cells exhibit aberrant 
accumulation of autophagosomes under starvation
Previously, we established a highly immune-resistant cervi-
cal cancer cell line, CaSki P3 (termed P3), which was 
generated from its immune susceptible parental cell line, 
HLA-A2+ CaSki P0 (termed P0), through three rounds of 
in vitro selection by mixing P0 cells pulsed with the HLA- 
A2-restricted MLANA/MART-1 peptide together with 
MLANA-specific T cells (clone KKM) [20]. To examine 
whether immune-selection affects autophagy, we monitored 
autophagosome formation in CaSki tumor cells, before (P0) 
or after (P3) immune-selection. There was no considerable 
difference in autophagosome abundance between the P0 
and P3 cells under normal serum conditions (Figure 1A). 
However, in the serum-starved condition, autophagosome 
abundance was significantly increased in P3 cells compared 
to P0 cells (Figure 1A). Because the lipidated form (LC3B- 
II) of LC3B is correlated with autophagosome abundance, 
we also estimated the absolute level of LC3B-II (normalized 
by ACTB/actin beta) under normal serum conditions or 
serum-starved conditions by western blot analysis. Relative 
to P0 cells, P3 cells exhibited elevated LC3B-II levels under 
starvation conditions, especially (Figure 1B). Furthermore, 
transmission electron microscopy (TEM) analysis revealed 
that relative to P0 cells, P3 cells exhibited an extensive 
accumulation of double and multi-membraned structures 
with a broad range of morphologies, presumably corre-
sponding to stalled autophagosomes or autolysosomes 
(Figure 1C). Interestingly, there was no significant altera-
tion in autophagic flux in P3 cells compared to P0 cell (Fig. 
S1). Instead, the increase in the amount of LC3B-II 
occurred in parallel with the change in the amount of 
total cellular LC3B in P3 cells relative to P0 cells (Figure 
1B). Therefore, our data suggest that immune-selection 
facilitates enrichment of a subset of tumor cells having an 
increase in autophagosome abundance rather than autopha-
gy flux.
Knockdown of ATG7 reverses immune resistant and 
CSC-like phenotypes in immune-refractory tumor cells
We previously demonstrated that the P3 tumor cells were 
refractory to apoptotic death by cognate CTLs, whereas the 
parental P0 tumor cells remained sensitive to these CTLs 
[20–22]. Because P3 tumor cells exhibit increased autopha-
gosome abundance, we postulated that autophagy could 
contribute to immune-resistant phenotype of tumor cells. 
To directly link autophagy to the phenotype of P3 tumor 
cells, we silenced the autophagy-related gene ATG7 in P3 
cells using siRNAs (Figure 1D). Knockdown of ATG7 
nearly abolished starvation-induced autophagy, shown by 
the markedly decreased conversion of LC3B-I to LC3B-II 
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Figure 1. Inhibition of autophagosome formation reverses CSC-like and immune-resistant phenotypes in immune-refractory tumor cells. (A and B) CaSki P0 and P3 
cells were incubated in medium supplemented with 10% or 0.1% FBS for 48 h. (A) The cells were stained with anti-LC3B (Red) antibodies and then visualized by 
confocal microscopy. DAPI was used to stain nuclei. The images are representative of three separate experiments. Scale bar: 10 µm. The graph depicts the 
experimental quantitation of puncta. (B) The protein levels of LC3B were determined by western blot analysis (numbers below each blot are densitometric values). 
The graphs represent quantification for absolute level of LC3B-II (upper) and total LC3B level (lower), respectively. (C) CaSki P0 and P3 cells starved for 48 h in 
medium supplemented with 0.1% FBS were fixed and imaged by transmission electron microscopy (TEM). Yellow arrows indicate autophagic vacuoles. Scale bar: 
1 µm. The graph shows the number of autophagic vacuole profiles per cell area. (D-G) CaSki P0 and P3 cells were transfected with siRNA targeting GFP or ATG7. (D) 
The protein levels of ATG7 and LC3B were determined by western blot analysis. ACTB was included as an internal loading control. Numbers below the blot images 
indicate the expression as measured by fold-change. (E and F) Flow cytometry analysis of the frequency of apoptotic (active CASP3+) cells (E) after incubation with or 
without MLANA-specific CTLs at a 1:1 ratio for 4 h or (F) after intracellular delivery of GZMB for 4 h. (G) The degree of CSC-like phenotypes was assessed by the
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and the defect in autophagosome formation (Figure 1D and 
S2). Notably, autophagy inhibition by ATG7 knockdown 
increased the sensitivity of P3 cells to apoptosis induced 
by antigen-specific CTLs (Figure 1E and S3), suggesting 
a crucial role of autophagy regulator ATG7 in resistance 
of the tumor cells to CTLs-mediated apoptosis.
It is conceivable that autophagy inhibition in tumor cells 
influences the antigen-presentation pathway, which could 
account for decreased sensitivity to apoptosis by CTLs. 
Indeed, increased autophagy in tumor cells was reported to 
affect the loss of MHC class I level on tumor cells [23]. We 
observed a slight or significant loss of the surface MHC class 
I level in tumor cells following immune selection (P0 vs. P3) 
or starvation (10% FBS vs. 0.1% FBS), respectively. However, 
it seems that the loss of MHC class I in P3 cells is independent 
of autophagy, as evidenced by failure to cause a change in the 
level of MHC class I upon knockdown of ATG7 or LC3B (Fig. 
S4). Importantly, P3 cells were also resistant to in vitro lipo-
somal delivery of GZMB (granzyme B), which is a key com-
ponent in CTL-mediated apoptosis and the resistant 
phenotype was reversed by ATG7 depletion (Figure 1F). 
Thus, our data indicate that autophagy renders immune- 
refractory tumor cells impervious to apoptotic death by 
CTLs, regardless of T-cell recognition.
Besides immune-resistance, P3 tumor cells have more 
tumorigenic and CSC-like properties relative to parental P0 
tumor cells [21]. Notably, siATG7-treated P3 cells decreased 
in vitro sphere-forming capacity and reduced tumor-initiating 
property when transplanted into NOD-SCID mice (Figure 
1G–I), suggesting that autophagy is important for mainte-
nance of CSC-like properties of P3 tumor cells. In contrast, 
ATG7 knockdown did not alter susceptibility to CTL and 
GZMB, sphere-forming capacity and tumor-initiating prop-
erty of P0 cells (Figure 1D–I). Taken together, these results 
suggest that, not necessarily autophagic flux per se, core 
autophagy regulator ATG7 plays an important role in 
immune-resistance and the CSC-like phenotype of P3 tumor 
cells.
NANOG regulates autophagosome abundance in tumor 
cells
We next attempted to elucidate the underlying mechanism 
responsible for an increase in autophagosome abundance in 
immune-resistant tumor cells. We previously discovered 
that NANOG is a key transcription factor driving the 
multi-modal resistance and CSC-like phenotype in 
immune-resistant P3 tumor cells [5,21]. Recently, it has 
also been reported that NANOG contributes to the activa-
tion of autophagy under metabolic stress, such as hypoxia 
[19]. As NANOG was upregulated upon immune-selection 
of CaSki cells (Figure 2A), we hypothesized that NANOG 
might be responsible for increased autophagosome abun-
dance in P3 cells. Indeed, knockdown of NANOG in P3 
cells led to significant decrease in LC3B-II levels and autop-
hagosome abundance (Figure 2A,B), suggesting a crucial 
role of NANOG in determining the autophagic state of P3 
cells. We then asked whether NANOG expression in P0 
cells could similarly induce the autophagic properties of P0 
cells to resemble those of P3 cells. Notably, delivery of 
NANOG to P0 cells raised the levels of LC3B-II, which 
was accompanied by increased levels of total LC3B but 
not by autophagy flux (Figure 2C and S5), and increased 
autophagosome abundance under starvation conditions 
(Figure 2D,E). Given these data, we conclude that 
NANOG is a critical mediator that could contribute to 
increase of autophagosome abundance in tumor cells facing 
starvation.
NANOG directly regulates LC3B through promoter 
occupancy.
To gain insights into understanding the mechanisms by which 
NANOG regulates autophagosome abundance in the 
immune-refractory tumor cells, we performed genome-wide 
total RNA-sequencing analysis in the P0 and P3 cells and 
compared the data with the ChIP-ChIP profiles for NANOG 
[24] in order to screen for putative NANOG target genes. 
Further, we compared the expression of genes involved in 
autophagosome formation among the putative NANOG target 
genes, upregulated in P3 cells relative to P0 cells (Figure 3A). 
Among the four autophagosome-related genes screened in 
this analysis, only LC3B expression was reversed by NANOG 
knockdown (Figure 3B), indicating a NANOG-dependent 
upregulation.
We next investigated whether NANOG regulates LC3B 
expression through its transcriptional function. To address 
this, we used a mutant form of NANOG (NANOGE264G, 
E268G,E272A, NANOG MUT) that was previously found to 
have weak transcriptional activity [5]. When we transfected 
CaSki and HEK293 cells with wild-type NANOG (NANOG 
WT), mRNA and protein of LC3B were profoundly increased, 
while NANOG MUT had no significant impact on either 
mRNA or protein levels of LC3B (Figure 3C,D), indicating 
that NANOG regulates LC3B expression through its tran-
scriptional function. To further elucidate the underlying 
mechanism by which NANOG regulated LC3B transcription, 
we identified the LC3B promoter region containing a putative 
NANOG-binding site (Figure 3E), suggesting the possibility 
that NANOG was a direct transcriptional activator of LC3B. 
Notably, chromatin immunoprecipitation (ChIP) assays con-
firmed the direct binding of NANOG to the regulatory region 
of the LC3B gene (Figure 3F), which was also validated in the 
CaSki P0 and P3 cells, where we noted more NANOG 
sphere-forming capacity in low-density suspension culture. The experiments were performed in triplicate. (H and I) At 16 h after siRNA transfection, 105 cells were 
subcutaneously inoculated into NOD/SCID (n = 6). (H) Tumor formation was monitored for 13 d. (I) At 13 d after injection, the tumor burden was excised and 
weighed. *p < 0.01, **p < 0.001 and ***p < 0.0001 by two-way ANOVA (E, F, G and I) or by 2-tailed Student’s t-test (A-C). The data represent the mean ± SD.
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occupancy in P3 cells, relative to the P0 cells (Figure 3G). These findings demonstrate that NANOG upregulates LC3B 
transcription by directly binding to its promoter region.
Figure 2. NANOG regulates autophagosome abundance in tumor cells. (A and B) CaSki P0 and P3 cells were transfected with siRNA targeting GFP or NANOG and 
were incubated in medium supplemented with 0.1% FBS for 48 h. (A) The protein levels of NANOG and LC3B were determined by western blot analysis (numbers 
below each blot are densitometric values). The graphs represent quantification for absolute level of LC3B-II (upper) and total LC3B level (lower), respectively. (B) The 
cells were stained with anti-LC3B (red) antibodies and then visualized by confocal microscopy. DAPI was used to stain nuclei. The images are representative of three 
separate experiments. Scale bar: 10 µm. The graph depicts the experimental quantitation of LC3B puncta. (C) CaSki-no insert and CaSki-NANOG cells were incubated 
in medium supplemented with 10% or 0.1% FBS for 48 h. The protein levels of LC3B were determined by western blot analysis (numbers below each blot are 
densitometric values). The graphs represent quantification for absolute level of LC3B-II (upper) and total LC3B level (lower), respectively. (D and E) CaSki-no insert and 
CaSki-NANOG cells were incubated in medium supplemented with 0.1% FBS for 48 h. (D) The cells were stained with anti-LC3B (red) antibodies and then visualized 
by confocal microscopy. DAPI was used to stain nuclei. The images are representative of three separate experiments. Scale bar: 10 µm. The graph depicts the 
experimental quantitation of LC3B puncta. (E) The cells were fixed and imaged by transmission electron microscopy (TEM). Yellow arrows indicate autophagic 
vacuoles. Scale bar: 2 µm. The graph shows the number of autophagic vacuole profiles per cell area. *p < 0.01 and **p < 0.001, by two-way ANOVA (A and B) or by 
2-tailed Student’s t-test (C, D and E). All experiments were performed in triplicate. The data represent the mean ± SD.
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LC3B promotes NANOG-dependent aggressive 
phenotypes through AKT signaling pathway
We then asked whether LC3B potentiates NANOG-mediated 
phenotypes. To directly link LC3B to these phenotypes, we 
silenced LC3B expression in CaSki-NANOG cells (Figure 4A). 
Notably, overexpression of NANOG in P0 cells decreased 
sensitivity of P0 cells to CTLs or GZMB without changing 
the level of MHC class I (Fig. S6) that could subsequently be 
reversed by LC3B knockdown (Figure 4B,C and S7A-S7C). 
Likewise, LC3B knockdown reduced CSC-like property of 
CaSki-NANOG cells (Figure 4D). Previously, we demon-
strated that NANOG promotes tumorigenicity and immune- 
Figure 3. NANOG directly regulates LC3B through promoter occupancy. (A) Venn diagram showing the overlap of genes with upregulated in CaSki P3 versus P0 (red), 
NANOG target genes from ChIP-ChIP data (blue) and autophagosome formation-related genes (black). (B) CaSki P0 and P3 cells were transfected with siRNA targeting 
GFP or NANOG, as indicated. mRNA expressions of LC3B, HSPA5, FEZ1 and FOXO1 were analyzed by qRT-PCR. (C and D) CaSki P0 or HEK 293 cells were transfected with 
empty vector (no insert), FLAG-NANOG wild type (NANOG WT), or FLAG-NANOGE264G;E268G;E272A (NANOG MUT). (C) LC3B mRNA levels were measured by qRT-PCR. (D) 
Levels of LC3B and FLAG-NANOG proteins were confirmed by western blot. (E) Diagram of the human LC3B promoter region containing the NANOG binding element. 
The arrows indicate qChIP-PCR amplicon. (F) The cross-linked chromatin from CaSki or HEK 293 cells transfected with empty vector or FLAG-NANOG was 
immunoprecipitated with mouse IgG or anti-FLAG antibodies. Relative enrichment of FLAG-NANOG on the LC3B promoter region was assessed by qChIP-PCR 
analysis with primers that amplify genomic region indicated above. The value of ChIP data represents relative ratio to the input. (G) Relative enrichment of NANOG 
on the LC3B promoter in CaSki P0 and P3 cells was determined by ChIP using anti-NANOG antibody, followed by qPCR analysis. All experiments were performed in 
triplicate under starved conditions with 0.1% FBS media. *p < 0.01 and **p < 0.001, by one-way ANOVA (B, C and D) or 2-tailed Student’s t-test (F and G). The data 
represent the mean ± SD.
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resistance of tumor cells through AKT-dependent upregula-
tion of CCNA1/cyclin A and MCL1 (MCL1 apoptosis regu-
lator, BCL2 family member), respectively [5]. Consistently, 
levels of p-AKT1, CCNA1, and MCL1 increased by NANOG 
were robustly dampened upon LC3B knockdown (Figure 4A). 
These results indicate that LC3B plays a crucial role in the 
AKT-dependent aggressive phenotypes of NANOG+ tumor 
cells.
LC3B is involved in EGF secretion resulting in activation 
of EGFR-AKT signaling
We next aimed to elucidate the role of LC3B in the 
NANOG-induced activation of AKT signaling. Since 
multiple receptor tyrosine kinases (RTKs) can mediate 
AKT signaling in tumor cells, a phosphor RTK antibody 
array was performed to identify the potential RTK 
responsible for AKT activation mediated by the 
NANOG-LC3B axis. From this analysis, we noted that 
the phosphorylation level of EGFR in the CaSki- 
NANOG cells was decreased by LC3B knockdown (Fig. 
S8 and 5A), and this was then confirmed by western 
blot analysis (Figure 5B). It has been documented that 
activation of the EGFR signaling pathway is mediated 
by EGF and its related ligands and that increased sti-
mulation of EGFR through the autocrine growth factor 
loops plays an important role in human cancers [25]. In 
this regard, we observed that levels of secreted EGF in 
the CaSki-NANOG cells were decreased by LC3B knock-
down (Figure 5C,D). Notably, EGF secretion by LC3B 
was regulated primarily at the post-translational level, 
rather than the transcriptional or translational levels, 
evidenced by the failure of LC3B knockdown to cause 
a change in mRNA or intracellular protein levels of EGF 
(Figure 5C,E). It had been shown that the secretion of 
several proteins is associated with the autophagy-based 
unconventional secretory pathway and that metabolic 
stress triggered unconventional protein secretion 
[26,27]. Consistently, our confocal microscopy analysis 
revealed that a part of intracellular EGF localized in the 
LC3B-positive puncta in tumor cells and that their co- 
localization was increased upon NANOG overexpression 
(Fig. S9). Likewise, we observed increased co- 
localization of EGF with LC3B-positive puncta in P3 
cells, compared to P0 cells (Fig. S10). We further inves-
tigated which stages of the autophagy pathway is 
involved in EGF secretion using two other autophagy 
inhibitors, spautin-1 and bafilomycin A1 (BafA1). 
Spautin-1 is a specific inhibitor of the PtdIns3K cataly-
tic subunit (PIK3C3/VPS34) that is responsible for 
autophagosome formation, whereas BafA1 is an inhibi-
tor of V-ATPase, which blocks the fusion of 
Figure 4. LC3B promotes NANOG-dependent aggressive phenotypes through the AKT signaling pathway. (A-D) CaSki-no insert cells and CaSki-NANOG cells were 
transfected with siGFP, siLC3B #1 or siLC3B #2 then incubated in medium supplemented with 0.1% FBS for 48 h. (A) The levels of LC3B, p-AKT1, AKT1, CCNA1, and 
MCL1 protein in these cells were analyzed by western blots. (B-C) Flow cytometry analysis of the frequency of apoptotic (active CASP3+) cells (B) after incubation with 
or without MLANA-specific CTLs at a 1:1 ratio for 4 h or (C) after intracellular delivery of GZMB for 4 h. (D) The degree of CSC-like phenotypes was assessed by the 
sphere-forming capacity in low-density suspension culture. All experiments were performed in triplicate. *p < 0.01 and **p < 0.001, by two-way ANOVA (B, C and D). 
The data represent the mean ± SD.
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autophagosomes to lysosomes [28]. Interestingly, 
increased EGF secretion in P3 tumor cells after 
immune-selection was strongly lessened by treatment 
with spautin-1 but not with BafA1 (Fig. S11A and 
S11B), indicating that autophagosome formation is 
important for EGF secretion in P3 cells, but late auto-
phagy components involved in autophagosome- 
lysosome fusion appear to be dispensable in the process. 
Notably, similar to LC3B knockdown, spautin-1 treat-
ment reduced EGF secretion and dampened the level of 
p-EGFR in NANOG-overexpressed tumor cells as well as 
P3 cells (Figure 5F and S11C). Taken together, these 
results suggest that LC3B upregulation by NANOG pro-
motes autophagosome-mediated EGF secretion, thereby 
activating the EGFR signaling pathway in tumor cells.
NANOG-LC3B-p-EGFR expression in human cervical 
neoplasia correlates with tumor progression and disease 
outcome
We previously observed that the expression level of NANOG 
correlates with tumor progression and poor outcome of 
patients with cervical cancer [5,29]. To determine the clinical 
relevance of the NANOG-LC3B-p-EGFR axis in human can-
cer, we first performed immunohistochemistry for LC3B and 
p-EGFR in cervical tissue specimens from patients with cer-
vical intraepithelial neoplasia (CIN) (Table S1) and further 
analyzed their relationship with previously reported NANOG 
[29]. We found that the levels of LC3B and p-EGFR were 
increased as tumor progressed from normal to low-grade CIN 
to high-grade CIN to cancer (Figure 6A and S12). Consistent 
with our in vitro experimental results, the level of LC3B 
Figure 5. LC3B is involved in EGF secretion resulting in activation of EGFR. (A-F) CaSki-NANOG cells were transfected with siGFP or siLC3B #1, then incubated in 
medium supplemented with 0.1% FBS for 48 h. (A) Representative dot images from the phospho-RTK array for p-EGFR levels in these cells. p-Tyr was included as an 
internal loading control. (B) The levels of p-EGFR, EGFR, and ACTB were confirmed by western blots. (C) The protein levels of secreted EGF and internal EGF were 
evaluated by western blot analysis of the conditioned medium and lysate of these cells. (D) The amount of EGF secreted into the media was measured by ELISA. (E) 
LC3B mRNA expression was analyzed by qRT-PCR. (F) In the cells treated with or without spautin-1, the protein levels of secreted EGF and internal EGF, p-EGFR, EGFR, 
LC3B and GAPDH were confirmed by western blots. The graphs represent quantification for relative levels of secreted EGF (upper) or p-EGFR (lower), respectively. All 
experiments were performed in triplicate. *p < 0.01, by 2-tailed Student’s t-test (D and E) and two-way ANOVA (F). NS, not significant. The data represent the mean ± 
SD.
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Figure 6. LC3B and p-EGFR significantly correlate with NANOG in human cervical neoplasia specimens. (A) Representative images of IHC staining of LC3B and p-EGFR 
in cervical tissue from normal, LGCIN, HGCIN, and cervical carcinoma patients. Scale bar: 25 µm. CIN, cervical intraepithelial neoplasia; LG-CIN, low-grade CIN; HG-CIN, 
high-grade CIN. (B) Correlation between each parameter. LC3B histoscore compared with NANOG and p-EGFR histoscores using a simple scatter plot. (C) Overall 
survival of cervical cancer patients was analyzed in Kaplan-Meier plots. Patients with high levels of LC3B and p-EGFR expression showed reduced overall survival (log- 
rank test, p = 0.003 and p = 0.004, respectively) compare with patients with low levels of LC3B and p-EGFR expression. Notably, patients with combined NANOG+ 
LC3B+, NANOG+ p-EGFR+, NANOG+ LC3B+ p-EGFR+ expression was showed significantly worse overall survival (log-rank test, p = 0.001, p = 0.002, and p = 0.005, 
respectively) than patients with NANOG− LC3B−, NANOG− p-EGFR−, NANOG− LC3B− p-EGFR− expression. LC3B+, histoscore > 145; p-EGFR+, histoscore > 172. The 
p-values by Spearman correlation (R) (B) or Log-rank (Mantel-Cox) test (C) were indicated.
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showed a strong positive correlation with that of p-EGFR 
(Spearman’s rho = 0.673, p < 0.001), and that of NANOG 
was also positively correlated with LC3B (Spearman’s 
rho = 0.628, p < 0.001) and p-EGFR (Spearman’s 
rho = 0.630, p < 0.001) (Figure 6B). We next examined the 
relationship of each protein level with patient survival out-
comes. Kaplan-Meier plots demonstrated that patients with 
high levels of LC3B or p-EGFR showed significantly worse 
overall survival than patients with low levels of LC3B or 
p-EGFR (Figure 6C). Furthermore, patients with combined 
NANOG+ LC3B+, NANOG+ p-EGFR+, or LC3B+ p-EGFR+ 
showed significantly worse overall survival than patients with 
NANOG− LC3B−, NANOG− p-EGFR−, or LC3B− p-EGFR− 
(Figure 6C). Similarly, patients with combined NANOG+ 
LC3B+ p-EGFR+ showed decreased overall survival compared 
to NANOG− LC3B− p-EGFR− patients (Figure 6C). 
Remarkably, the Cox proportional hazards model revealed 
that high LC3B, p-EGFR levels and the combined levels of 
NANOG, LC3B, and p-EGFR were independent prognostic 
factors for overall survival (Table 1). Taken together, we 
conclude that the NANOG-LC3B-p-EGFR axis is conserved 
in patients with cancer and serves as an important prognostic 
factor in human cervical cancer.
LC3B promotes immune-resistance and CSC-like 
properties via the EGF-EGFR-AKT axis
Given the crucial role of the LC3B in NANOG-mediated 
aggressive phenotypes, we reasoned that LC3B expression 
alone could promote these properties. Indeed, transfection 
of CaSki P0 cells with LC3B (LC3B WT) induced the 
phosphorylation of EGFR and AKT, and increased levels 
of CCNA1 and MCL1 protein (Figure 7A). Furthermore, 
overexpression of LC3B WT in P0 cells induced resistance 
to CTLs or GZMB without any change of the MHC class 
I level (Figure 7B,C and S13A), and conferred a CSC-like 
phenotype (Figure 7D). Interestingly, we didn’t observe any 
changes in the levels of the stemness factors including 
NANOG upon LC3B overexpression (Fig. S13B), suggesting 
that LC3B is capable of inducing these phenotypes, regard-
less of stemness factor upregulation in tumor cells.
However, addition of LC3B lacking the C-terminal gly-
cine (LC3BΔG120), a mutant that cannot be lipidated [30], 
failed to markedly induce the activation of EGFR-AKT 
signaling as well as immune-resistance and CSC-like phe-
notype (Figure 7A–C), indicating an important role of 
LC3B lipidation on those properties. Notably, knockdown 
of ATG7, an autophagy-related E1-like enzyme essential for 
LC3B lipidation, robustly reduced the level of p-EGFR and 
p-AKT, increased GZMB-mediated apoptosis, and, consis-
tently, decreased sphere-forming capacity of CaSki-LC3B 
cells (Fig. S14A-S14C). These data further support 
a crucial role of LC3B lipidation, dependent upon core 
ATG genes such as ATG7, in immune resistance and CSC- 
like property of tumor cells.
Notably, LC3B WT-transfected cells had markedly higher 
levels of EGF secretion, compared with empty vector- or 
LC3BΔG120-transfected cells (Figure 7E). The neutraliza-
tion of secreted EGF by its specific monoclonal antibody 
led to a significant decrease in the phosphorylation levels of 
EGFR and AKT in CaSki-LC3B cells, suggesting a direct 
role for EGF in the LC3B-induced EGFR signaling pathway 
(Figure 7F). Furthermore, knockdown of EGFR reversed the 
resistance of LC3B-transfected tumor cells to GZMB and 
diminished the sphere-forming capacity of these tumor cells 
with a concomitant reversal of AKT activation (Figure 7G– 
I). Taken together, our findings indicate that LC3B by itself 
was sufficient to confer immune-resistance and CSC-like 
phenotypes of tumor cells via EGF-EGFR-AKT signaling 
axis, dependent on its lipidation by core ATG genes.
LC3B inhibition sensitizes NANOG+ immune-refractory 
tumor to adoptive transfer of T cell clone
Given our observations in vitro, we reasoned that inhibi-
tion of LC3B could serve as an interventional strategy for 
reversing the resistance of tumor cells to T cell-based 
immunotherapy. To evaluate this idea, we used human 
MLANA-specific T cells (clone KKM), specific for the 
HLA-A2-restricted epitope (M27) of the tumor-associated 
antigen, MLANA. Because CaSki cells rarely express 
MLANA antigen, we chose another immune-resistant 
human cancer cell line, MDA-MB231 P3, which was 
Table 1. Univariate and multivariate analyzes of overall survival in cervical cancer patients.
Variables
Univariate analysis Multivariate analysis
Hazard ratio [95% CI] p value Hazard ratio [95% CI] p value
Age (>50) 0.94 [0.39–2.25] 0.897 NA
FIGO stage (> IIB) 4.21 [1.79–9.89] 0.001 3.94 [1.37–11.31] 0.011
Cell type (non-SCC) 3.00 [1.21–7.42] 0.017 2.99 [1.18–7.56] 0.021
Grade (poor) 2.42 [1.02–5.75] 0.045 2.01 [0.82–4.91] 0.124
Tumor size (>4 cm) 1.95 [0.82–4.62] 0.129 NA
LN metastasis 2.25 [0.82–6.17] 0.114 NA
LC3B+ a 4.64 [1.52–14.13] 0.007 3.37 [1.06–10.73] 0.039
p-EGFR+ b 6.64 [1.52–29.01] 0.012 5.03 [1.12–22.53] 0.034
NANOG+ LC3B+ 4.54 [1.93–10.63] <0.001 3.80 [1.51–9.56] 0.005
NANOG+ p-EGFR+ 2.92 [1.25–6.80] 0.013 3.00 [1.23–7.33] 0.016
NANOG+ LC3B+ p-EGFR+ 3.57 [1.48–8.59] 0.004 2.77 [1.08–7.09] 0.033
acut-off value of LC3B+ is over 145 of IHC score; bcut-off value of p-EGFR+ is over 172 of IHC score; CI, confidence interval; FIGO, International Federation of 
Gynecology and Obstetrics; LN, lymph node; NA, not applicable 
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previously established by three rounds of in vivo selection 
with MLANA-specific CTLs from its parental HLA-A2+ 
MDA-MB231 cells, which highly expressed the MLANA 
antigen [21]. To demonstrate the therapeutic value of 
inhibiting LC3B, we inoculated MLANA+ MDA-MB231 
P3 cells into NOD-SCID mice and intravenously adminis-
tered chitosan nanoparticles (CNPs) carrying LC3B- or 
GFP (green fluorescent protein)-targeting siRNA 10 
d later (Figure 8A). Eleven days after the tumor challenge, 
the mice received an adoptive transfer of MLANA-specific 
CTLs (Figure 8A). While immunotherapy alone had no 
effect on tumor growth, the delivery of siLC3B elicited 
a moderate therapeutic effect (Figure 8B–D). Importantly, 
combined therapy with siLC3B and adoptive transfer pro-
foundly retarded tumor growth (Figure 8B,C) and pro-
longed survival of the mice (Figure 8D). In agreement 
with our in vitro results, we observed reduced levels of 
p-EGFR, p-AKT, MCL1, and CCNA1 in tumor tissue from 
siLC3B-treated mice compared with those from siGFP- 
treated mice (Figure 8E). Additionally, the siLC3B-treated 
tumors contained fewer proliferating cells than the siGFP- 
treated tumors, measured by MKI67 staining, and this was 
unaffected by adoptive transfer (Figure 8F). We assessed 
the antigen-specific CTL infiltration into the tumor by 
Figure 7. LC3B promotes immune-resistance and CSC-like properties through the EGF-EGFR-AKT axis. (A-E) CaSki P0 cells were transfected with empty vector (no 
insert), GFP-LC3B wild-type (WT), or GFP-LC3B ΔG120, then incubated in medium supplemented with 0.1% FBS for 48 h. (A) The levels of GFP-LC3B, p-EGFR, EGFR, 
p-AKT1, AKT1, CCNA1, and MCL1 were analyzed by western blots. Numbers below the blots are densitometric values. (B-C) Flow cytometry analysis of the frequency 
of apoptotic (active CASP3+) cells (B) after incubation with or without MLANA-specific CTLs at a 1:1 ratio for 4 h or (C) after intracellular delivery of GZMB or 4 h. (D) 
The degree of CSC-like phenotypes was assessed by the sphere-forming capacity in low-density suspension culture. (E) The amount of EGF secreted into the media 
was measured by ELISA. (F) CaSki-no insert and CaSki-LC3B cells were treated with IgG or anti-EGF antibodies, as indicated. The levels of p-EGFR, EGFR, p-AKT1, and 
AKT1 were analyzed by western blots. Numbers below the blots are densitometric values. (G-I) CaSki-no insert and CaSki-LC3B cells were transfected with siGFP or 
siEGFR, as indicated. (G) The levels of p-EGFR, EGFR, p-AKT1, and AKT1 were analyzed by western blots. Numbers below the blots are densitometric values. (H) Flow 
cytometry analysis of the frequency of apoptotic (active CASP3+) cells in the cells after intracellular delivery of GZMB for 4 h. (I) The degree of CSC-like phenotypes 
was assessed by the sphere-forming capacity in low-density suspension culture. All experiments were performed in triplicate. *p < 0.01 and **p < 0.001, by two-way 
ANOVA (B, H and I) or one-way ANOVA (C, D, and E). The data represent the mean ± SD.
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labeling the T cells with carboxyfluorescein succinimidyl 
ester (CFSE) prior to adoptive transfer, then counting the 
number of CFSE+ cells inside the tumor following the 
transfer. The frequency of tumor-infiltrating T cells in 
the tumors from siLC3B-treated mice was not significantly 
different from that in siGFP-treated mice (Figure 8G and 
S15). However, the CTL-mediated cytotoxic effects, which 
indicated the percentage of apoptotic tumor cells, were 
greater after delivery of the siLC3B relative to after the 
delivery of siGFP (Figure 8H), suggesting that enhanced 
cytotoxic effect of CTLs is not as a result of difference in 
CTL infiltration, but rather due to increased susceptibility 
of tumor cells to CTLs. Taken together, we conclude that 
inhibition of LC3B is able to reverse the resistant pheno-
type of the immune-refractory tumor cells and represents 
an attractive, widely applicable strategy for the control of 
human cancer, either as a sole modality or synergistically 
as part of a T cell-based immunotherapy.
Lc3b inhibition renders NANOG+ immune-refractory 
tumor susceptible to anti-PDCD1-mediated anti-tumor 
immunity
We next assessed whether the NANOG-LC3B axis would also 
be responsible for the refractoriness to immune checkpoint 
blockade (ICB) therapy. To do this, we selected B16-F10 
murine tumor cell line with high levels of NANOG and 
LC3B (Figure 9A). Indeed, the murine tumor cells were pre-
viously reported to be relatively refractory to ICB therapy 
[31]. Consistently, knockdown of Nanog robustly dampened 
the levels of LC3B as well as p-EGFR and p-AKT (Fig. S16A). 
Notably, knockdown of Lc3b resulted in identical effects on 
the level of these molecules compared with treatment with 
siNanog, although it did not affect NANOG protein level (Fig. 
S16A). Furthermore, siNanog- or siLc3b-treated B16F10 cells 
were more susceptible to GZMB-mediated apoptosis, and they 
also had diminished sphere-forming capacity, compared with 
Figure 8. In vivo targeting of autophagy in immune-refractory tumor cells potentiates the antitumor effects of CTL in a preclinical cancer model. (A) Schematic of the 
therapy regimen in mice implanted with MDA-MB231 P3 cells. (B) Tumor growth, (C) mass (at 21 d after challenge), and (D) survival of mice inoculated with MDA- 
MB231 P3 treated with the indicated reagents. (E) Western blot analysis of LC3B, p-EGFR, EGFR, p-AKT1, AKT1, MCL1, and CCNA1 protein in mice administered siGFP 
or siLC3B #1, with or without adoptive transfer of MLANA-specific CTLs. (F) The proliferation index of cells inside the tumor, as measured by the mean fluorescence 
intensity of MKI67 staining. (G) Flow-cytometric analysis of the frequency of CFSE-labeled MLANA-specific CTL in the tumors of mice with or without adoptive transfer 
of CFSE-labeled MLANA-specific CTL. (H) The frequency of apoptotic cells in the tumors of siGFP- or siLC3B #1-treated mice, with or without adoptive transfer of 
MLANA-specific CTL. For the in vivo experiments, five mice from each group were used. *p < 0.01 and **p < 0.001, by two-way ANOVA (B), one-way ANOVA (C, F, and 
H), or log-rank test (D) or 2-tailed Student’s t-test (G). The data represent the mean ± SD.
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siGFP-treated tumor cells (Fig. S16B and S16C). These results 
demonstrate that the biochemical and functional properties of 
immune-refractory NANOG-LC3B axis are conserved in 
B16F10 cells, and that LC3B is a key molecule downstream 
of NANOG signaling and capable of phenocopying NANOG.
To investigate whether inhibition of LC3B could overcome 
the resistance to ICB therapy in vivo, we treated B16-F10 
tumor-bearing mice with anti-PDCD1 antibody along with 
siLc3b (Figure 9B). Consistent with our in vitro results, we 
observed reduced levels of p-EGFR, p-AKT1, MCL1, and 
CCNA1, without changing the levels of stemness factors 
including NANOG in tumor tissues from siLc3b-treated 
mice compared with that from siGFP-treated mice (Fig. S17A- 
S17C). The combination of siLc3b and anti-PDCD1 antibody 
conferred a remarkable therapeutic effect and improved sur-
vival compared to either treatment alone (Figure 9C–E), indi-
cating that Lc3b inhibition reversed the refractory phenotype 
of tumor cells to ICB therapy. Moreover, we found that the 
percentage of apoptotic tumor cells was increased in the 
combined treatment compared to either treatment alone 
(Figure 9F). Accumulating evidence suggests that tumor cell 
death in anti-tumor therapy can lead to the release of tumor 
antigens that prime the subsequent auto-loop of anti-tumor 
immune responses (known as “the cancer-immunity cycle”) 
[32–34]. Therefore, we postulated that Lc3b inhibition, along 
with anti-PDCD1 treatments, inflames tumor immune 
Figure 9. LC3B inhibition renders the tumor susceptible to anti-PDCD1-mediated anti-tumor immunity. (A) Western blot analysis of LC3B and NANOG expression in 
various mouse cancer cell lines. (B) Schematic of the therapy regimen in mice implanted with B16F10 cells. (C) Tumor growth, (D) mass at 20 d after challenge, and 
(E) the survival of the mice inoculated with B16F10 treated with the indicated reagents. (F) The frequency of apoptotic cells in the tumors of siGFP- or siLc3b 
#1-treated mice, with or without anti-PDCD1 treatment. (G) Flow cytometry profiles of tumor-infiltrating CD3+ and CD8A+ T cells. (H) The ratio of GZMB+ to tumor- 
infiltrating CD3+ CD8A+ T cells. (I) Quantification of antigen-specific CTLs in tumors (left), draining lymph nodes (middle), or spleens (right) derived from the tumor- 
bearing mice. For the in vivo experiments, 10 mice from each group were used. *p < 0.01 and **p < 0.001, by two-way ANOVA (C, D and F-I), or log-rank test (Mantel- 
Cox) (E). The data represent the mean ± SD.
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environments by reversing the resistance of immune- 
refractory tumor cells to T cell-mediated cytotoxicity. 
Indeed, the number of overall CD8A+ T cells and tumor- 
reactive CD8A+ T cells with GZMB were significantly higher 
in the combined treatment group compared to the other 
treatment groups (Figure 9G,H, S18A and S18B), indicating 
that the infiltration of tumor-reactive CD8A+ T cells was 
enhanced by the combined treatment. To test whether the 
generation of tumor-reactive T cells was affected by dual 
treatment, we isolated cells from tumors, draining lymph 
nodes, and spleens of mice who received therapy and were 
then stimulated ex vivo with either DMSO (control) or PMEL/ 
gp100 peptide. Notably, the number of PMEL/gp100-specific 
CD8A+ T cells was drastically increased in the combined 
treatment group compared to the other treatment groups 
(Figure 9I and S18C-S18E). Taken together, our results 
demonstrate that Lc3b inhibition enhanced the response to 
ICB therapy by switching immune phenotypes from “immune 
deserts” to “inflamed”, as well as by reversing the resistance of 
tumor cells to ICB therapy.
Discussion
Immunological pressures drive the adaptation of tumor cells 
to host immune surveillance. This adaptation may occur 
through host-intrinsic events, such as the induction of 
tumor antigen-specific T-cell tolerance or the establishment 
of an immunosuppressive-tumor microenvironment by 
recruiting Tregs or myeloid-derived suppressor cells [35]. 
Alternatively, it may be controlled by tumor-intrinsic events, 
such as loss of antigen or MHC class I, or gain of CD274/PD- 
L1 expression or resistance to apoptosis [36–38]. 
Accumulating evidence indicate that immune selection also 
closely linked to the emergence of tumor cells refractory to 
multiple clinical interventions, including immunotherapy 
[22,36,39]. Notably, the selection by immune system, together 
with clonal evolution of malignant cells, contributes to the 
generation of cancer cells that have better survival advantages 
and eventually leads to the enrichment of immune-refractory 
cancer cells with unique features including CSC-like proper-
ties [2,5]. Here, we showed that the refractory phenotypes of 
tumor cells over the course of immune-selection are closely 
linked to an aberrant autophagy state accompanied by autop-
hagosome accumulation via transcriptional induction of LC3B 
by a stem cell factor NANOG. Further, to our knowledge, we 
are the first to report a role of NANOG-LC3B axis in 
immune-refractory cancer.
An intriguing question that remains to be answered is the 
precise role of autophagy in the process of tumor adaptation 
to host immune defense. It had been documented that auto-
phagy may act as a negative regulator of MHC class 
I molecule, critical to immune recognition [23]. Despite 
a slight loss of the surface MHC class I level in cancer cells 
over the course of immune-selection, the level of MHC-I was 
not reversed by depletion of autophagy component ATG7 or 
LC3B, suggesting other mechanisms that may contribute to 
the loss of MHC-I during immune-selection. Indeed, regula-
tion of MHC expression occurs through a combination of 
cytokines, transcription factors, and epigenetic modifications 
[40–42]. Importantly, besides resistance to CTLs, P3 tumor 
cells were also resistant to GZMB, a key component in CTL- 
mediated apoptosis. Consistent with our results from CTL 
assay, these resistant phenotypes were reversed by depletion 
of autophagy component ATG7 or LC3B. The results indicate 
the crucial roles of autophagy process in anti-apoptotic prop-
erties tumor cells, regardless of T cell recognition.
The upregulation of LC3B has been reported in multiple 
human carcinomas [43–45]. However, its regulatory mechan-
ism, particularly in the course of cancer evolution, has not yet 
been extensively studied. In this regard, we noted that 
immune pressure imposed by immunotherapeutic agents, 
such as vaccination and Ag-specific CTLs, drives the acquisi-
tion of NANOG, a master transcription factor that mediates 
the emergence of a stem-like cancer cell state and immune 
evasion [3–5]. In this study, we demonstrated that LC3B is 
a novel NANOG transcriptional target, suggesting that 
NANOG facilitates autophagosome accumulation by directly 
upregulating LC3B expression. Importantly, our results also 
demonstrate that LC3B is a key component of several 
NANOG-dependent phenotypes. Notably, after the depletion 
of LC3B, the CSC-like and immune-resistant phenotype of 
NANOG-transduced P0 cells was almost entirely lost. These 
results provide insights into the direct link between the 
NANOG-induced aggressive phenotypes and LC3B-mediated 
autophagic states in tumor cells.
Given the crucial role of the NANOG-LC3B axis in the 
development of immune-resistant phenotypes, we believe that 
inhibition of LC3B may be an effective strategy to control 
immune-refractory tumor cells. We provided proof of this 
concept by knocking down LC3B in a xenograft mouse 
model with two kinds of immune-refractory tumor cells. 
Expectedly, knockdown of LC3B in MDA-MB231 P3 tumor 
cells following immune-selection restored sensitivity to CTL 
killing and effectively controlled tumor growth in mice trans-
ferred with tumor-specific CTLs. Furthermore, LC3B inhibi-
tion enhanced the anti-tumor effects of anti-PDCD1 therapy 
in B16F10 tumors, which had no significant response to anti- 
PDCD1 therapy. Intriguingly, the combination of LC3B inhi-
bition and anti-PDCD1 therapy further increased the traffick-
ing of effector CD8A+ T cells to the tumors, indicating a shift 
of tumor immune environments to “inflamed-tumor.” In this 
regard, it has been well-documented that tumor cell death by 
T cells could lead to the release of tumor antigens that prime 
subsequent immune responses, known as the cancer- 
immunity cycle [32–34]. Accumulating evidence suggests 
that initiating or re-invigorating the cancer-immunity cycle 
triggers the switch of immune phenotypes from “immune- 
excluded” or “immune deserts” to “inflamed tumor” [46–48]. 
Thus, our results indicate that LC3B inhibition induces 
“inflamed” immune phenotypes by reversing the resistance 
to T-cell-mediated cytotoxicity in tumor microenvironments, 
indicating the re-invigoration of the cancer-immunity cycle.
Studies have reported that LC3B was associated with dis-
ease progression, chemo-resistance, and metastatic potential 
in multiple human cancers [43,49]. With regard to the auto-
phagy phenomenon, this raises the obvious questions: (a) 
How does LC3B contribute to immune-resistance and the 
CSC-like phenotype and (b) is LC3B alone capable of 
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promoting these features? Our study focused on a growing 
appreciation for a novel role of autophagy in cellular secretion 
[50]. In particular, we found that NANOG-LC3B axis con-
tributed to the secretion of EGF, thereby activating EGFR 
signaling. Furthermore, LC3B expression by itself was suffi-
cient to confer these aggressive phenotypes in a lipidation- 
dependent manner. Notably, after knockdown of EGFR, the 
CSC-like and immune-resistant phenotype of LC3B- 
transduced P0 cells was almost entirely lost, indicating that 
the EGFR pathway was one of primary routes through which 
LC3B acted to promote these phenotypes. Although it will be 
important in future studies to assess the precise underlying 
mechanisms by which LC3B regulates EGF secretion, this 
connection immediately hints at several potentially promising 
therapeutic targets to control immune-refractory cancer in the 
clinic.
It is important to note that the role of autophagy in the 
maintenance of CSC-like features within cancer cells 
remains complex and controversial. Previous studies 
reported that autophagy can have a tumor suppressor func-
tion and is often downregulated in specific CSCs [51,52]. 
Nevertheless, it is well documented that CSCs are charac-
terized by elevated levels of autophagy compared to non- 
CSCs [51]. Accumulating evidence indicates that autophagy 
helps to maintain the stemness of CSCs and results in the 
failure of anticancer therapy [53]. Interestingly, although 
inhibition of LC3B leads to a significant decrease in CSC- 
like property of immune-refractory tumor cells, LC3B did 
not influence the levels of stemness factors including 
NANOG. In light of this, our data propose that gain of 
LC3B might be a result of the immune selection of 
NANOG+ immune-refractory tumor cells but not a cause 
at least during immune selection. We don’t exclude the 
possibility, however, that the gain of LC3B may confer 
survival advantage to NANOG+ tumor cells by enabling 
a better autophagic response to limited nutrient supply.
Notably, we found that the level of LC3B protein, in addi-
tion to NANOG [3], was elevated in multiple types of human 
cancer cells. This underscores the value of LC3B as 
a prognostic factor in cervical neoplasia, and it strongly sug-
gests that the functions of LC3B in tumor cells that were 
observed in vitro hold true for cancer patients, as well. 
Importantly, LC3B levels in cervical cancer tissues were posi-
tively correlated with levels of NANOG and EGFR phosphor-
ylation, thus validating the proposed biochemical pathway. 
The molecular axis of NANOG-LC3B-p-EGFR may also be 
critically related to the progression of cervical neoplasia, as we 
have supporting data showing that the degree of the molecular 
axis was correlated with cervical cancer phenotypes and worse 
prognosis in patients.
Taken together, in this report, we propose that NANOG+ 
cancer cells enriched by immune selection preferentially 
expressed LC3B via transcriptional regulation. In the selection 
process, LC3B promoted immune resistant and CSC-like phe-
notypes through hyperactivation of the EGFR-AKT functional 
axis. Therefore, our data provide evidence that the inhibition 
of LC3B may be a promising strategy that will help combat 
NANOG+ immune-refractory tumors, particularly in regard 
to immune-based cancer therapy.
Materials and Methods
Mice
Six- to eight-week-old female NOD-SCID or C57BL/6 mice 
were purchased from Central Lab. Animal Inc. (Seoul, Korea). 
All mice were maintained and handled under the protocol 
approved by the Korea University Institutional Animal Care 
and Use Committee (KOREA-2017-0141). All animal proce-
dures were performed in accordance with recommendations 
for the proper use and care of laboratory animals.
Cell lines
CaSki, MDA-MB231, HEK293, and B16F10 cell lines were 
purchased from American Type Culture Collection (CRL- 
1550, HTB-26, CRL-1573 and CRL-6475). All cell lines were 
obtained between 2010 and 2014, and tested for mycoplasma 
using the Mycoplasma Detection Kit (Thermo Fisher 
Scientific, 4460626). The identities of the cell lines were con-
firmed by short tandem repeat (STR) profiling by IDEXX 
Laboratories Inc. and were used within six months for testing. 
The generation and maintenance of the immune-resistant 
CaSki P3 [20] and MDA-MB P3 [21] cell lines have been 
previously described. The CaSki-NANOG cell line has been 
previously described [21]. All cells were grown at 37°C in 
a 5% CO2 incubator/humidified chamber.
Chemical reagents
The following chemical reagents were used in this study: 
spautin-1 (Selleckchem, S78880) and bafilomycin A1 (Sigma- 
Aldrich, B1793-2UG).
siRNA constructs
Synthetic small interfering RNAs (siRNAs) specific for GFP, 
ATG7, NANOG, LC3B, EGFR, Nanog and Lc3b were pur-
chased from Bioneer (Korea): nonspecific GFP (green fluor-
escent protein), 5ʹ-GCAUCAAGGUGAACUUCAA-3ʹ 
(sense), 5ʹ-UUGAAGUUCACCUUGAUGC-3ʹ (antisense); 
ATG7 #1, 5ʹ-CAGCUAUUGGAACACUGUA-3ʹ (sense), 5ʹ- 
UACAGUGUUCCAAUAGCUG-3ʹ (antisense); ATG7 #2, 
5ʹ-CAGCUAUUGGAACACUGUA-3ʹ (sense), 5ʹ- 
UACAGUGUUCCAAUAGCUG-3ʹ (antisense); NANOG 
#1, 5ʹ-GCAACCAGACCUGGAACAA-3ʹ (sense), 5ʹ-UUG 
UUCCAGGUCUGGUUGC-3ʹ (antisense); NANOG #2 5ʹ- 
CUAAACUACUCCAUGAACA-3ʹ (sense), 5ʹ-UGU 
UCAUGGAGUAGUUUAG-3ʹ (antisense); EGFR, 5ʹ- 
GAUCCACAGGAACUGGAUA-3ʹ (sense), 5ʹ- UAUCCAG 
UUCCUGUGGAUC-3ʹ (antisense); LC3B #1, 5ʹ- 
CAUAAAGACACCACUCAAA-3ʹ (sense), 5ʹ- 
UUUGAGUGGUGUCUUUAUG-3ʹ (antisense); LC3B #2, 
5ʹ-CAUAAAGACACCACUCAAA-3ʹ (sense), 5ʹ- 
UUUGAGUGGUGUCUUUAUG-3ʹ (antisense); and Lc3b 
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#1, 5ʹ-UCAGGUACAAGGAACUUUGUU-3ʹ (sense), 5ʹ- 
CAAAGUUCCUUGUACCUGAUU-3ʹ (antisense); Lc3b #2 
5ʹ-GUGGUUGUCAAGUGGUAGA-3ʹ (sense), 
5ʹUCUACCACUUGACAACCAC-3ʹ (antisense; Nanog 5ʹ- 
CAGAUAGGCUGAUUUGGUU-3ʹ (sense), 5ʹ- 
AACCAAAUCAGCCUAUCUG-3ʹ (antisense). For in vitro 
delivery, the cells were transfected with 100 pmol of synthe-
sized siRNAs using Lipofectamine 2000 (Invitrogen, 
11,668,027) according to the manufacturer’s instructions. 
For the systemic in vivo delivery of siRNA into tumor 
cells, we prepared the characterized CNP as described pre-
viously [54].
DNA constructs
The pMSCV-FLAG-NANOG WT and pMSCV-FLAG- 
NANOGE264G;E268G;E272A plasmids have been described 
previously [5]. The pEX-GFP-hLC3WT and the pEX- 
GFP-hLC3ΔG120 plasmid was a gift from Isei Tanida 
(Addgene, 24987, 24988) [30].
Immunofluorescence
Cells grown on 4-well cell culture slides (SPL life science, 
30404) were fixed with 4% paraformaldehyde (Wako, 
30525–89-4) in phosphate-buffered saline (PBS; Biosesang, 
P2007-1) for 20 min, and then blocked with 5% normal goat 
serum (NGS, Thermo Fisher Scientific, 50062Z) in PBS for 
1 h. The cells were incubated with primary antibodies and 
appropriate secondary antibodies conjugated to Alexa Fluor 
488 or 555 (Invitrogen, A11001, A21429). Confocal fluores-
cence images were obtained using a Zeiss LSM700 confocal 
microscope (Carl Zeiss). Image analysis was performed using 
ImageJ. For calculation of the Pearson correlation coefficient, 
single cells were marked and analyzed with the JACoP plugin 
for ImageJ (NIH).
Electron microscopy analysis
Cells were incubated in medium supplemented with 0.1% FBS 
for 48 h. The cells were washed with 0.1 M PBS (pH 7.0) and 
fixed with a buffer containing 2% paraformaldehyde and 2.5% 
glutaraldehyde (Electron microscopy sciences, 16310) in PBS 
at room temperature for 30 min. After washing with PBS, cells 
were post-fixed with 1% osmium tetroxide (Heraeus, 
89.740.219) for 90 min, dehydrated and then embedded with 
Epoxy resin mixture (epon-812; Electron microscopy sciences, 
14120). Thin sections of 70 nm were collected on 200-mesh 
nickel grid (Electron microscopy sciences, EMS200-Ni) and 
stained with uranyl acetate (Electron microscopy sciences, 
22400) followed by lead citrate. Electron microscopy observa-
tion for general morphology was performed using a Hitachi 
H-7650 electron microscopy (Hitachi High-Technology Co.) 
with 80 kV acceleration voltage.
Real-time quantitative RT-PCR
Total RNA was isolated using the RNeasy Micro kit 
(Qiagen, 74004), and the cDNAs were synthesized by 
reverse transcriptase (RT) using the iScript cDNA 
synthesis kit (Bio-Rad, 1708891), according to the man-
ufacturer’s recommended protocol. Real-time quantita-
tive PCR was performed using iQ SYBR Green Supermix 
(Bio-Rad, 1708882AP) with the following specific pri-
mers: LC3B, 5ʹ-TGTCCGACTTATTCGAGAGCAG-3ʹ 
(forward) and 5ʹ-TCACTCATGTTGACATGGTCAGG 
-3ʹ (reverse); FEZ1, 5ʹ-GCTTTCGGAACTACAACGCC 
-3ʹ (forward) and 5ʹ-CATCCCAAACCTCCTCGTCC-3ʹ 
(reverse); FOXO1, 5ʹ-GTGGAGATCGACCCGGACTT 
-3ʹ (forward) and 5ʹ-CCGAGTTGGACTGGCTAAAC-3ʹ 
(reverse); HSPA5, 5ʹ- AGACGGGCAAAGATGTCAGG- 
3ʹ (forward) and 5ʹ-GCCCGTTTGGCCTTTTCTAC-3ʹ 
(reverse); EGF, 5ʹ-GGATGGGATGTCCTCTTGCC-3ʹ 
(forward) and 5ʹ- ACCCAGGAGCCAGGGATAA-3ʹ 
(reverse); and ACTB, 5ʹ-CGACAGGATGCAGAAGGAG 
−3ʹ (forward) and 5ʹ-TAGAAGCATTTGCGGTGGAC 
−3ʹ (reverse) in a CFX96 real-time PCR detection sys-
tem. All real-time quantitative PCR experiments were 
performed in triplicate and quantification cycle (Cq) 
values were determined using Bio-Rad CFX96 Manager 
3.0 software. Relative quantification of the mRNA levels 
was performed using the comparative Ct method with 
ACTB as the reference gene.
Western blot analysis
Lysate extracted from a total of 1 × 105 cells was used to 
perform western blot analysis as described previously [55]. 
Primary antibodies against LC3B (2775S), ATG7 (8558S), 
p-AKT1 (9271), AKT1 (9272), MYC/c-MYC (D84C12), 
p-EGFR (3777S), EGFR (4267S) were purchased from Cell 
Signaling Technology. Primary antibodies against FLAG 
(M185-3 L), GFP (2555) and ACTB (M177-3) were pur-
chased from Medical & Biological Laboratories. Primary anti-
bodies against MCL1 (sc-819), KLF4 (sc-20,691), POU5F1/ 
OCT4 (sc-9081) were purchased from Santa Cruz 
Biotechnology. Primary antibodies against NANOG (Bethyl 
Laboratories, A300-397A) and EGF (Abcam, ab206106) were 
also used in western blot analysis, followed by the appropriate 
secondary antibodies conjugated with horseradish peroxi-
dase. The immunoreactive bands were developed using the 
chemiluminescence ECL detection system (Elpis Biotech, 
EBP1073), and the signals were detected using 
a luminescent image analyzer (LAS-4000 Mini, Fujifilm). 
ACTB was included as an internal loading control. The 
intensity of the western blot signals was quantified using 
Multi-gauge software (Fujifilm).
Quantitative ChIP (qChIP) assays
The ChIP kit (Millipore, 17–295) was used according to the 
manufacturer’s instructions and the ChIP assay was per-
formed as described previously [56]. Immunoprecipitation 
was carried out by incubation with 1 µg of anti-NANOG 
(Bethyl Laboratories, A300-397A), anti-FLAG (Medical & 
Biological Laboratories, M185-3 L) antibodies or rabbit IgG 
(Millipore, PP64) for 16 h, and then the immunoprecipitated 
DNA was quantified by real-time qPCR using the following 
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primer sets: 5ʹ-CAGAGTAACCCTGGCCCATT-3ʹ (forward) 
and 5ʹ-ATTTTCCCACCCTTGGGCAT-3ʹ (reverse). Each 
sample was assayed in triplicate, and the amount of precipi-
tated DNA was calculated as the percentage of the input 
sample.
Antibody arrays of phospho-RTK
Phospho-RTK arrays were performed according to the manu-
facturer’s recommendations (Human phospho-RTK Array Kit, 
R&D Systems, ARY001B). Briefly, phospho-RTK array mem-
branes were blocked with 5% BSA (Biosesang, 9048–46-8) in 
TBS (0.01 M Tris-HCl, pH 7.6) for 1 h. Then, the membranes 
were incubated with 200 μg of total protein for 16 h at 4°C. 
After extensive washing with TBS, the membranes were incu-
bated with anti-phospho-tyrosine HRP antibody for 2 h at room 
temperature. The unbound HRP antibody was washed out with 
TBS containing 0.1% Tween-20 (Biosesang, TR1027-500-00). 
Finally, each array membrane was developed using the chemi-
luminescence ECL detection system (Elpis Biotech, EBP1073), 
and signals were detected using a luminescent image analyzer 
(Fujifilm, LAS-4000 Mini).
EGF assessment of medium supernatants
The cells were grown in 6-well plates and incubated with 
medium containing 0.1% FBS for 48 h at 37°C. The super-
natants were collected and centrifuged to remove cell debris. 
The EGF levels in the supernatants were measured by the 
Quantikine Human EGF ELISA kit (R&D Systems, DEG00). 
For western blot analysis, the supernatants were further con-
centrated 30X by Centricon Plus-70 centrifugal Filter Units-3 
kDa (Millipore, UFC800324).
CTL-mediated apoptosis assay
For CTL-mediated apoptosis assay, MLANA-specific KKM 
CTL clone [57], specific for the HLA-A2-restricted epitope 
(M27) of the tumor-associated MLANA antigen was used. 
HLA-A2+ CaSki cells were labeled with 10 μM of CFSE 
(Sigma-Aldrich, 21888) in DMEM supplemented with 0.1% 
FBS. The CFSE-labeled cells were pulsed with HLA- 
A2–restricted MLANA M27 peptide (AAGIGILTV, 1 μg/ml) 
or NY-ESO-1 peptide (SLLMWITQC, 1 μg/ml) for 1 h, then 
mixed with cognate MLANA-specific CD8A+ CTLs at a 1:1 
ratio and incubated for 4 h at 37°C. The cells were stained for 
active CASP3 (caspase 3, BD biosciences, 51–68655X) as an 
index of apoptosis and examined by flow cytometry as 
described previously [5].
GZMB-mediated apoptosis assay
Human GZMB (Enzo Life Sciences, BML-SE238-5000) was 
introduced into cells with the BioPORTER QuikEase Protein 
Delivery Kit (Sigma-Aldrich, BPQ96). 1 × 105 cells per well 
were plated in 12-well plates and cultured overnight at 37°C. 
Cells were washed, and 100 ng of GZMB in Opti-MEM 
(Thermo Fisher Scientific, 31985070) was added to each 
well. After incubation for 4 h at 37°C, the frequency of 
apoptotic cells was determined by staining with anti-active 
CASP3 antibody (BD biosciences, 51–68655X) and perform-
ing flow cytometry.
MHC class I expression measurement
To confirm expression of the class I molecule of the major 
histocompatibility complex (MHC), CaSki cells were stained 
with PE Mouse anti-human leukocyte antigen-A2 (HLA-A2), 
(BD biosciences, 558,570) or isotype control (BD biosciences, 
555,743) in cold PBS with 0.1% BSA for 30 min at 4°C. A BD 
FACSVerse™ was used to carry out flow cytometry analysis.
Tumor sphere-forming assay
The cells were seeded at 1 × 103 cells per well in 24-well ultra- 
low attachment plate (Corning, 3473) containing serum-free 
DMEM-F12 (GE Healthcare Life Sciences, SH30023.01) sup-
plemented with 20 ng/ml of EGF (Gibco, PHG0315), 20 ng/ml 
of basic FGF (Gibco, 13,256–029), and 1X B27 (Gibco, 17,-
504–044). The medium was replaced every 3 d to replenish 
nutrients. Colonies more than 50 um in diameter were 
counted under a microscope.
In vivo tumorigenicity assay
The cells were harvested by trypsin treatment, then washed 
and resuspended in Opti-MEM. NOD/SCID mice were sub-
cutaneously injected with 105 cells. Tumor formation was 
monitored every 2 d. After 12 d, tumor tissue was excised 
and weighed.
Total RNA sequencing
For control and test RNAs, rRNA was removed using the 
Ribo-Zero Magnetic Kit (Epicenter, MRZ116 C) from each 
5 μg of total RNA. A library was constructed using the SENSE 
Total RNA-Seq Library Prep Kit (Lexogen, 009.24) according 
to the manufacturer’s instructions. The library production was 
initiated by the random hybridization of starter/stopper het-
erodimers to the remaining RNA. These starter/stopper het-
erodimers contained Illumina-compatible linker sequences. 
A single-tube reverse transcription and ligation reaction 
extended the starter to the next hybridized heterodimer, 
where the newly synthesized cDNA insert was ligated to the 
stopper. Second-strand synthesis was performed to release the 
library from the beads, and the library was then amplified. 
Barcodes were introduced when the library was amplified. 
High-throughput sequencing was performed as paired-end 
100 sequencing using HiSeq 2000 (Illumina Inc.). Total RNA- 
Seq reads were mapped using TopHat software tool in order 
to obtain bam file (alignment file). Read counts mapped on 
transcripts region were extracted from the alignment file 
using bedtools (v2.25.0) and Bioconductor that uses 
R (version 3.2.2) statistical programming language [58]. The 
alignment file also was used for assembling transcripts, esti-
mating their abundances and detecting differential expression 
of genes. And we used the fragments per kilobase of exon 
per million (FPKM) fragment as the method of determining 
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the expression level of the gene regions. Global normalization 
method was used for comparison between samples. The acces-
sion number for the sequencing data reported in this article is 
GEO: GSE128729.
Tissue samples and immunohistochemistry
Tissue samples were prospectively collected via surgery from 
the Department of Obstetrics and Gynecology of Gangnam 
Severance Hospital between 1996 and 2010. Some of the 
paraffin blocks were provided by the Korea Gynecologic 
Cancer Bank through the Bio & Medical Technology 
Development Program of the Ministry of Education, Science 
and Technology, Korea (NRF-2017M3A9B8069610). Tumor 
specimens from 398 patients with primary cervical cancer or 
cervical intraepithelial neoplasia (CIN) and 245 matched nor-
mal epithelium tissues were constructed into Tissue tissue 
microarrays (TMAs) as previously described [5]. Written 
informed consent was obtained from all patients who enrolled 
in this study. This study was approved by the Institutional 
Review Board of Gangnam Severance Hospital (Seoul, South 
Korea) and all procedures were conducted in accordance with 
the guidelines of the Declaration of Helsinki.
Immunohistochemistry (IHC) was performed on the TMA 
slides as described elsewhere. Sections (5 µm) were cut from 
the TMA block and deparaffinized in xylene and rehydrated 
through a graded alcohol series. Antigen retrieval was per-
formed using a pressure chamber (Pascal; Dako) with pH 6.0 
Target Retrieval Solution (Dako, GV80511-2). Endogenous 
peroxidase activity was blocked by incubation in 3% H2O2 
(Milipore, 7722–84-1) for 10 min. The sections were incu-
bated with anti-LC3B antibodies (Abcam, ab48394) diluted 
1:1000 for 1 h or anti-p-EGFR antibodies (Cell Signaling 
Technology, 2236S) diluted 1:100 for 1 h. Subsequently, the 
antigen-antibody reaction was detected with the EnVision+ 
Dual Link System-HRP (Dako, K406311-2) and visualized 
with 3,3-diaminobenzidine (DAB+; Dako, K3468) for 
10 min. The TMA sections were lightly counterstained in 
a Mayer’s hematoxylin bath and examined by light micro-
scopy. Negative control immunoglobulin G (IgG) was used in 
place of primary antibody to evaluate nonspecific staining and 
the TMA included appropriate positive control specimens. 
NANOG levels were previously examined in the same cohort 
[29].
The stained TMA sections were digitized using the 
NanoZoomer 2.0 HT (Hamamatsu Photonics K.K.) at X20 
objective magnification. Digital analysis of the images was 
performed using the Visiopharm Integrator System 
v6.5.0.2303 (VIS; Denmark). The percentage of stained cells 
was recorded for each intensity of staining (from 0 to 3) for 
each TMA core and the histoscore (range; 0 to 300) was 
obtained by multiplying the intensity and the percentage.
Tumor treatment experiments
NOD/SCID mice were inoculated subcutaneously with 2 × 106 
MDA-MB231 P3 cells per mouse. Ten days following the tumor 
challenge, siGFP- or siLC3B #1-loaded CNPs (7 μg/mouse) were 
administered via intravenous route. The day after siRNA 
treatment, the mice have received an adoptive transfer of 
2 × 106 MLANA-specific CTLs. This treatment regimen was 
repeated for three cycles. To assess the frequency of tumor- 
infiltrating MLANA-specific CTLs, MLANA-specific CTLs 
were labeled with CFSE and adoptively transferred into the 
mice at the last injection. The mice were monitored for tumor 
burden and survival for 20 and 40 d after the challenge, respec-
tively. C57BL/6 mice were inoculated subcutaneously with 
1 × 105 B16-F10 cells per mouse. Five days following the 
tumor challenge, siGFP- or siLc3b #1-loaded CNPs (7 μg/ 
mouse) were administered via intravenous route. The day 
after siRNA treatment, the mice were administered 200 μg of 
anti-PDCD1/PD-1 (BioXcell, RMP1-14) or an isotype antibody 
control, which was administrated three times intraperitoneally 
every 2 d. This treatment regimen was repeated for three cycles. 
The mice were monitored for tumor burden and survival 20 and 
40 d after the challenge, respectively.
Immune cell tumor infiltration
The treated C57BL/6 mice were sacrificed on day 20 following 
tumor inoculation, and the tumors were harvested. The 
tumors were dissected into fragments by cutting and disso-
ciating using by a cell strainer. The cell suspensions were 
stained for intracellular and extracellular protein markers of 
interest. The stained samples were assessed on a flow cyt-
ometer (BD Bioscience, BD FACSVerse™) along with BD 
FACSuite software. The staining antibodies were as follows: 
anti-CD3 (Biolegend, 100236), anti-CD8A (BD Biosciences, 
553031), anti-GZMB (Biolegend, 372208).
Analysis of generation of antigen-specific T- cells
To investigate the generation of tumor antigen-specific 
CD8A+ T cells, treated C57BL/6 mice were sacrificed on day 
20 following tumor inoculation and the tumors, draining 
lymph nodes, and spleens were harvested and incubated 
with either DMSO (Daejung, 67–68-5) or PMEL/gp100 pep-
tide (KVPRNQDWL, Fisher scientific, NC0888171) at 1 μg/ml 
for 24 h and stained with anti-CD8A (BD Biosciences, 
553031). Cell fixation and permeabilization were conducted 
thereafter with the CytoFix/CytopermTM kit (BD biosciences, 
554714), followed by washing with cold PBS and labeling with 
anti-IFNG (BD Biosciences, 554412). Flow cytometer cytome-
try, along with BD FACSuite software, was used to quantify 
the frequency of antigen-specific IFNG+, CD8A+ T cells.
Statistical analysis
All data are representative of at least three separate experi-
ments. Statistical differences were calculated by either 
Student’s t-test (two-tailed, unpaired), one-way ANOVA, or 
two-way ANOVA using GraphPad Prism 7 (GraphPad 
Software, Inc). For tissue samples and immunohistochemistry, 
statistical tests were performed using IBM SPSS statistics ver-
sion 21.0 (IBM Corporation). The Kruskal–Wallis or Mann– 
Whitney U test and x2-test were used to compare the protein 
expressions between each group. Survival curves were esti-
mated using the Kaplan-Meier method, and statistical 
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significance was calculated by the log-rank test. The Cox 
proportional hazards model was used for univariate and mul-
tivariate analyzes to determine the independent significance of 
each prognostic covariate. For all tests, a p-value < 0.05 was 
considered statistically significant.
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